BBIO:NSD-BridgeBio Pharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.25

Change

-0.23 (-2.19)%

Market Cap

USD 1.52B

Volume

1.75M

Avg Analyst Target

USD 24.33 (+137.40%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BridgeBio Pharma Inc (BBIO) Stock Analysis:
Based on the BridgeBio Pharma Inc stock forecasts from 4 analysts, the average analyst target price for BridgeBio Pharma Inc is USD 24.33 over the next 12 months. BridgeBio Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BridgeBio Pharma Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, BridgeBio Pharma Inc’s stock price was USD 10.25. BridgeBio Pharma Inc’s stock price has changed by -1.51% over the past week, -30.37% over the past month and -83.56% over the last year.

About

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in deve ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.76 (-3.03%)

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

-18.29 (-2.94%)

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.57 (-1.12%)

USD57.63B 27.19 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+5.51 (+3.65%)

USD36.62B 4.77 5.67
BGNE BeiGene Ltd

-15.38 (-6.18%)

USD25.75B N/A N/A
SGEN Seagen Inc

-4.45 (-3.43%)

USD23.69B 55.02 44.86
GMAB Genmab A/S

-1.55 (-4.54%)

USD22.21B 50.69 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.34 (-0.86%)

USD16.38B 19.81 11.89

ETFs Containing BBIO

Symbol Name Weight Mer Price(Change) Market Cap
IBBJ Defiance Nasdaq Junior Bi.. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.55% 6% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.55% 6% F 4% F
Trailing 12 Months  
Capital Gain -83.56% 9% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.56% 9% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 34.01% 69% D+ 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.01% 69% D+ 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 53.32% 57% F 31% F
Risk Adjusted Return 63.78% 92% A- 81% B-
Market Capitalization 1.52B 86% B 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 123.68 0% N/A 1% F
Price / Cash Flow Ratio -3.79 42% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,789.67% 2% F 1% F
Return on Invested Capital -91.65% 22% F 9% F
Return on Assets -42.63% 19% F 6% F
Debt to Equity Ratio 821.77% 1% F 2% F
Technical Ratios  
Short Ratio 2.29 60% D- 51% F
Short Percent 18.20% 5% F 9% F
Beta 0.61 78% C+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector